France Diabetes Drugs Market Analysis Report 2022 to 2030

France Diabetes Drugs Market Analysis

$ 3999

The France diabetes drugs market size was valued at $1.69 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030 and will reach $2.52 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The France diabetes drug market will grow because there is a growing focus on preventive measures to reduce the risk of developing diabetes, including lifestyle changes, which is also driving the demand for diabetes management products and services. The key market players are Adocia (FRA), Voluntis (FRA), Biocorp (FRA), CERBA HealthCare (FRA), Boehringer Ingelheim, Sanofi, and others.

ID: IN10FRPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Chandani Patel

Buy Now

France Diabetes Drugs Market Executive Summary

The France diabetes drugs market size was valued at $1.69 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030 and will reach $2.52 Bn in 2030. France is the world's sixth-largest economy in terms of nominal GDP, with a nominal GDP of approximately $2.7 trillion in 2021, according to the International Monetary Fund. France has a universal healthcare system, known as the "Sécurité Sociale," which is funded through a combination of taxes, social security contributions, and out-of-pocket payments. In 2021, France's healthcare expenditure was estimated to be approximately 11.4% of its GDP, according to the World Bank.

According to the International Diabetes Federation, the prevalence of diabetes in France was estimated to be 4.3% in 2021, which equates to approximately 3.2 Mn adults living with the condition. This high prevalence of diabetes in France has led to a significant impact on the diabetes drugs market. The demand for diabetes drugs in France has increased in recent years, and it is expected to continue growing in the coming years.

In particular, the market for oral antidiabetic drugs has been growing steadily, driven by an increase in the number of people with type 2 diabetes, which is the most common type of diabetes in France. The market for insulin has also been growing, as many people with type 2 diabetes eventually require insulin treatment. In addition to traditional diabetes drugs, there has been a growing interest in new classes of diabetes drugs, such as GLP-1 receptor agonists and SGLT-2 inhibitors, which have shown promising results in clinical trials. The high prevalence of diabetes in France has led to a large and growing market for diabetes drugs, with opportunities for pharmaceutical companies to develop new and innovative treatments to meet the needs of this patient population.

france diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

Rising prevalence of diabetes: The prevalence of diabetes in France is increasing, which is driving demand for diabetes drugs. This is due to factors such as aging population, increasing adoption of unhealthy lifestyles, and genetic factors.
Advancements in diabetes treatments: The development of new diabetes drugs and advancements in existing treatments are driving growth in the market. Newer drugs such as GLP-1 receptor agonists and SGLT-2 inhibitors have shown promising results in clinical trials and are driving growth in the market.
Increasing healthcare expenditure: The French government has been investing in healthcare infrastructure and healthcare services, which is driving growth in the diabetes drugs market.
Technological advancements: Technological advancements in diabetes monitoring devices, such as continuous glucose monitoring devices and insulin pumps, are also driving growth in the market.

Market Restraints

High cost of diabetes drugs: The high cost of diabetes drugs is a major restraint in the French market. Many patients cannot afford the cost of newer diabetes drugs, which is limiting the growth of the market.
Stringent regulatory requirements: The regulatory requirements for diabetes drugs are stringent, which is making it difficult for new players to enter the market.
Adverse side effects: Some diabetes drugs have adverse side effects, which is a concern for patients and is limiting the growth of the market.
Lack of awareness: Many patients are unaware of the importance of diabetes management and the benefits of newer diabetes drugs, which is limiting the growth of the market.

Competitive Landscape

Key Players

Adocia (FRA)
Voluntis (FRA)
Biocorp (FRA)
CERBA HealthCare (FRA)
Boehringer Ingelheim
Sanofi
Boehringer Ingelheim
Eli Lilly and Company
AstraZeneca
Johnson & Johnson
Bayer Pharmaceuticals
Novo Nordisk
Merck
Novartis
GlaxoSmithKline

Notable deals

In 2021, the Sanofi announced a collaboration with Google Cloud to use artificial intelligence and machine learning to improve diabetes care and outcomes.
In 2021, the Adocia announced a licensing agreement with Mediolanum Farmaceutici to commercialize its BioChaperone Glucagon in Italy.
In 2021, the Voluntis announced a partnership with Roche Diabetes Care to integrate its Insulia software with Roche's insulin delivery devices.
In 2021, the CERBA HealthCare announced the acquisition of Bio7, a French medical laboratory company that specializes in diabetes testing..

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The regulation of diabetes drugs in France is carried out by the French National Agency for Medicines and Health Products Safety (ANSM). ANSM is responsible for regulating the safety, efficacy, and quality of medicines in France, including diabetes drugs.

Marketing Authorization: Diabetes drugs must obtain marketing authorization from ANSM before they can be marketed in France. The marketing authorization process involves a rigorous evaluation of the safety, efficacy, and quality of the drug.

Pharmacovigilance: Pharmaceutical companies are required to monitor the safety of their diabetes drugs and report any adverse events to ANSM. ANSM also carries out post-marketing surveillance of diabetes drugs to ensure their safety.

Labeling Requirements: Diabetes drugs must have clear and accurate labeling that includes information on the indications, contraindications, and possible side effects of the drug.

Pricing and Reimbursement: The price of diabetes drugs in France is regulated by the French National Authority for Health (HAS), which determines the maximum price that can be charged for each drug. Diabetes drugs that are reimbursed by the French healthcare system must also meet certain criteria related to their efficacy and cost-effectiveness.

Clinical Trials: Clinical trials of diabetes drugs in France must comply with strict ethical and regulatory requirements, including obtaining informed consent from participants and following Good Clinical Practice guidelines.

In France, diabetes drugs are partially reimbursed by the national health insurance system. The reimbursement system is managed by the French National Authority for Health (HAS), which determines which drugs are eligible for reimbursement and at what level. Diabetes drugs are divided into different categories based on their level of effectiveness and cost. The reimbursement level for each drug is determined based on its category, with higher levels of reimbursement for more effective and cost-effective drugs. Patients are required to pay a co-payment for reimbursed diabetes drugs. The amount of the co-payment depends on the drug's reimbursement level and the patient's income.

To be eligible for reimbursement, diabetes drugs must be prescribed by a doctor and dispensed by a licensed pharmacist. Patients are required to present their health insurance card when filling a prescription. New diabetes drugs are subject to a reimbursement review by HAS, which evaluates their efficacy and cost-effectiveness before determining their reimbursement

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.